Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford, in partnership with the Royal College of Surgeons (RCS) and the Rosetrees Trust, are delighted to announce two new professorial posts.

From left to right: Ann Berger from Rosetrees Trust, Richard Ross from Rosetrees Trust, Professor David Beard, Professor Michael Douek and Vineeth Rajkumar from Rosetrees Trust

Professor David Beard is the newly appointed Director of the RCS Surgical Intervention Trials Unit (SITU) NDORMS and Professor Michael Douek, the newly appointed Director of the RCS SITU Nuffield Department of Surgical Sciences (NDS).

The appointments will add to growth in surgical clinical research activity, both nationally and internationally. Professors Beard and Douek will work closely with the RCS Surgical Trials Initiative, other RCS Professorial Chairs, RCS Surgical Trials Centres and Surgical Specialty Leads, to further clinical research activity across the UK.

Commenting on the new appointments Professor Derek Alderson, President of the Royal College of Surgeons, said:

“The RCS is very pleased to be working with the University of Oxford and the Rosetrees Trust, who are long-term supporters of research at the RCS. Together we will continue our commitment to improve clinical research in all areas and ultimately provide patients with an increased level of care.”

The appointments will act as key links between Surgical Trails Centres and National Clinical Research Networks to aid in the development of new trials, establish clinical networks and develop and deliver innovative trials.

Richard Ross, Chairman of Rosetrees Trust, said:

“Rosetrees is delighted to fund these positions jointly with the University of Oxford and the RCS surgical trials initiative. Rosetrees hopes the RCS tradition of creating awards for ground-breaking research will be reflected in the work these two outstanding Professors will undertake in the coming years and we look forward to a long and fruitful association.”

Now with frameworks, methodology and surgical trial units in the UK all well established, this next phase will see further developments linked to the Future of Surgery, automation, big data, global health and the further advances addressing the methodological nuances of evaluating a complex intervention such as surgery. - Profesor David Beard

Commenting on the new appointments, Head of Department for NDORMS Professor Andrew Carr said:

“We are very excited to welcome both Professor Douek and Professor Beard to SITU and the Botnar Research Centre as the Rosetrees RCS Directors. They both have a wealth of valuable experience in surgical trials which will allow them to successfully lead and further expand our work in this critical area of research activity, for the benefit of surgical patients in the UK and worldwide.”

Speaking on his appointment, Professor Beard said:

“I am honoured and delighted to be appointed to this new role. The Rosetrees Foundation have been an essential ingredient in RCS’ surgical evaluation initiative for several years. Their generous support and insight has been a leading factor in the overall success of the surgical trial development in this country.

“The added formal connection with the Medical Sciences Division here at Oxford creates a further formidable partnership. Now with frameworks, methodology and surgical trial units in the UK all well established, this next phase will see further developments linked to the Future of Surgery, automation, big data, global health and the further advances addressing the methodological nuances of evaluating a complex intervention such as surgery.

“While the need for quality trials remains ever present, consideration must extend to all stakeholders. Naturally the welfare of patients is foremost, but some balance will be required for the needs of surgeons, clinicians, practitioners, innovative industry partners and healthcare commissioners.

“The surgical evaluation team may be a relatively ‘new kid’ on the block in evaluative science, but its role will become increasingly important for healthcare provision of the future. I very much look forward to being a part of that exciting process.”

Of his appointment, Professor Douek said:

“I am passionate about surgical research and very excited to take on this role. I am driven by the conviction that novel surgical techniques and clinical devices should be evaluated with the same rigour and governance as established in drug clinical trials”.

News item courtesy of the Royal College of Surgeons

Funders

            Royal College of Surgeons logo

Rosetrees Trust logo

 

Similar stories

3,400 different medicines used globally to treat COVID-19

Main Statistics and epidemiology

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.